|
Jul 26
|
AstraZeneca CEO talks dual supply chain strategy
|
|
Jul 25
|
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
|
|
Jul 25
|
US economy keeps growing, Astrazeneca CEO describes challenges: Catalysts
|
|
Jul 25
|
AstraZeneca CEO: We're building '2 supply chains' to avoid impact of US-China tensions
|
|
Jul 25
|
Top Midday Stories: US Advance Q2 GDP Rises; Initial Jobless Claims Drop; Ford Earnings Fall; TotalEnergies' Lower Results; AbbVie Raises Guidance; IBM, ServiceNow Report Higher Results
|
|
Jul 25
|
Why AstraZeneca Stock Is Sliding Today
|
|
Jul 25
|
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
|
|
Jul 25
|
Why AstraZeneca's CEO isn't worried about costs
|
|
Jul 25
|
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
|
|
Jul 25
|
Astrazeneca (AZN) Reports Q2 Earnings: What Key Metrics Have to Say
|
|
Jul 25
|
NHS spending rules risk depriving Britain of new medicine, warns AstraZeneca boss
|
|
Jul 25
|
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
|
|
Jul 25
|
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
|
|
Jun 26
|
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
|
|
Jun 26
|
Novo Nordisk, Eli Lilly still top 2 pharma stocks: Analyst
|
|
Jun 26
|
China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
|
|
Jun 26
|
AstraZeneca’s Tagrisso receives approval in Japan for lung cancer
|
|
Jun 25
|
AstraZeneca makes another obesity play funnelling $80m into SixPeaks Bio
|
|
Jun 25
|
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
|
|
Jun 25
|
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
|